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generative disorders, like polyglutamine disorders (polyQ),
including Machado-Joseph disease (MJD), is the formation
of protein aggregates. MJD is caused by a CAG repeat expan-
sion in the ATXN3 gene, resulting in an abnormal protein,
which is prone to misfolding and forms cytoplasmic and
nuclear aggregates within neurons, ultimately inducing neu-
rodegeneration. Treatment of proteinopathies with drugs
that up-regulate autophagy has shown promising results in
models of polyQ diseases. Temsirolimus (CCI-779) inhibits
the mammalian target of rapamycin (m-TOR), while lithium
chloride (LiCl) acts by inhibiting inositol monophosphatase,
both being able to induce autophagy. We have previously
shown that chronic treatment with LiCl (10.4 mg/kg) had
limitedeﬀects in a transgenicMJDmousemodel. Also, others
have shown that CCI-779 had mild positive eﬀects in a diﬀer-
ent mouse model of the disease. It has been suggested that
the combination of mTOR-dependent and -independent
autophagy inducers could be a more eﬀective therapeutic
approach. To further explore this avenue toward therapy,
we treated CMVMJD135 transgenic mice with a conjugation
of CCI-779 and LiCl, both at concentrations known to induce
autophagy and not to be toxic. Surprisingly, this combined
treatment proved to be deleterious to both wild-type (wt)
and transgenic animals, failing to rescue their neurological
symptoms and actually exerting neurotoxic eﬀects. These
results highlight the possible dangers of manipulating
autophagy in the nervous system and suggest that a better
understanding of the potential disruption in the autophagy
pathway in MJD is required before successful long-term
autophagy modulating therapies can be developed.
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INTRODUCTION
Machado–Joseph disease (MJD), also known as
Spinocerebellar Ataxia type 3 (SCA3), is the most
common autosomal dominant ataxia worldwide (Maciel
et al., 1995), and is caused by a CAG repeat expansion
within the coding region of the ATXN3 gene (Kawaguchi
et al., 1994). The clinical severity and the age at onset
of the disease depend on the length of the expanded
repeat (Paulson, 1999; Gusella and MacDonald, 2000).
MJD is characterized by motor uncoordination and
amyotrophy, spasticity, gait ataxia, diﬃculty with speech
and swallowing, altered eye movements, double vision,
and frequent urination (Coutinho and Sequeiros, 1981;
Sequeiros and Coutinho, 1993).
MJD shares many features with other polyglutamine
diseases, such as the formation of cytoplasmic and
nuclear inclusion bodies within neurons by the mutant
protein (Becher et al., 1998; Wolozin and Behl, 2000). It
is assumed that the common toxic gain-of-function mech-
anisms for the polyglutamine-containing protein depend
on aggregation and deposition of misfolded proteins lead-
ing to neuronal dysfunction and eventually cell death
(Winklhofer et al., 2008).
Despite the well-described clinical and pathological
phenotypes, the molecular and cellular events
underlying neurodegeneration in these disorders are still
poorly understood. Compelling evidence points to major
etiological roles for interference with transcriptional
regulation, protein aggregation and clearance, the
ubiquitin–proteasome system and alterations of calcium
homeostasis in the neuronal loss observed during the
neurodegenerative process. These pathways could act
independently or, more likely, interact and enhance
each other, triggering the accumulation of cellular
damage that eventually leads to dysfunction and death
(Duenas et al., 2006). This suggests that simultaneous
targeting of several pathways may be therapeutically nec-
essary to prevent neurodegeneration and preserve neu-
ronal function. Understanding how dysregulation of
these pathways mediates disease progression is leading
to the ﬁrst attempts of obtaining eﬀective therapeutic
strategies in vivo, which may prove beneﬁcial in the treat-
ment of polyglutamine disorders (polyQ). One such
pathway is autophagy, a process that encompasses lyso-
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defective organelles and unfolded/aggregated proteins.
Autophagy is morphologically deﬁned by the appearance
of numerous cytosolic autophagosomes, which are
formed by the assembly and expansion of double layered,
membrane bound structures of unknown origin around
whole organelles and isolated proteins. The autophago-
somes encapsulate cytosolic materials and subsequently
dock and fuse with lysosomes or other vacuoles, resulting
in the degradation of their contents (Kelekar, 2005). In
several neurological diseases, the pathological accumula-
tion of autophagosomes/autophagosome-like structures
and abnormalities in the endosomal–lysosomal pathway
have been documented by electron microscopy (EM) in
human post mortem brain tissue (Cataldo et al., 1996;
Anglade et al., 1997; Nixon et al., 2005; Yu et al., 2005;
Moreira et al., 2007). While initially this was interpreted
as evidence of death triggered by autophagy, the cur-
rently predominant perspective is that this vesicle accu-
mulation reﬂects impaired autophagy completion, which
is emerging as a common element to several neurode-
generative disorders (Boland et al., 2008; Martinez-
Vicente et al., 2010). Autophagy induction has therefore
been advanced as a promising therapeutic strategy for
these diseases (Menzies et al., 2010; Spilman et al.,
2010), and in the particular case of MJD, genetic
approaches in lentiviral overexpression models have sup-
ported this conclusion (Nascimento-Ferreira et al., 2011).
The mammalian target of rapamycin (mTOR) kinase is
a master negative regulator of autophagy (Levine and
Klionsky, 2004). mTOR is a central sensor of energy sta-
tus, growth factors and nutrient signals, and can be inhib-
ited by rapamycin (Rubinsztein et al., 2007) and related
small molecules (Zhang et al., 2007). Besides this path-
way, autophagy can also be regulated independently of
mTOR (Sarkar et al., 2005). Inhibition of inositol
monophosphatase (IMPase) reduces free inositol and
IP3 levels, which leads to an upregulation of autophagy.
Rapamycin has been shown to reduce aggregation of
expanded polyQ in transfected cells (Ravikumar et al.,
2002), to protect against neurodegeneration in a ﬂy model
of Huntington disease (HD), and to improve motor perfor-
mance and decrease aggregate formation in a mouse
model of HD (Ravikumar et al., 2004). Lithium chloride
(LiCl), an mTOR-independent autophagy inducer has
been shown to improve motor performance and
depressive-like behavior in a mouse model of HD, as well
as to improve neuropathology and motor function in a
SCA1 mouse model (Wood and Morton, 2003; Watase
et al., 2007). We have recently shown that 19 weeks of
LiCl (10.4 mg/kg) treatment in the CMVMJD135 mouse
model, had limited eﬀects on the motor phenotype of
these animals, despite its ability to induce autophagy both
in the chronic and acute treatment (Duarte-Silva et al.,
2014). CCI-779, a less toxic rapamycin analogue, was
recently approved by the Food and Drug Administration
(FDA) for the treatment of renal cell carcinoma
(Kwitkowski et al., 2010; Bergmann et al., 2014). This
drug was shown to reduce mutant ataxin-3 levels and
toxicity, as well as ameliorate the disease symptoms ina transgenic mouse model of MJD (Menzies et al.,
2010). Additionally, Menzies and colleagues suggested
that the use of combined LiCl and CCI-779 would be an
interesting approach to explore (Sarkar et al., 2009).
The theoretical basis for this combinatory approach would
be the fact that LiCl can act both as an autophagy inducer
or inhibitor, depending on the dose used (Stambolic et al.,
1996; Sarkar et al., 2005). At higher dosages LiCl is actu-
ally able to inhibit GSK3, which suppresses autophagy via
phosphorylation of mTOR (Stambolic et al., 1996; Chiu
and Chuang, 2010); thus, a combinatory therapy with
another mTOR-dependent autophagy inducer could
counteract this eﬀect. The main goal of this work was to
test the potential of this combinatory treatment in MJD.
We treated transgenic models of MJD in Caenorhabditis
elegans and mouse (Teixeira-Castro et al., 2011; Silva-
Fernandes et al., 2014b) with a combination of CCI-779
and LiCl (m-TOR-dependent and independent pathways,
respectively). We show that the combinatory treatment
using LiCl and CCI-779 improved locomotion defects in
the transgenic C. elegans model of MJD. However, our
results show that the simultaneous administration of LiCl
and CCI-779 was ineﬀective in rescuing the motor impair-
ments of CMVMJD135 mice and had deleterious eﬀects
both in CMVMJD135 and wild-type (wt) animals at the
doses used in this pre-clinical trial.EXPERIMENTAL PROCEDURES
Nematode strains and general methods
Standard methods were used for culturing and observing
C. elegans (Brenner, 1974). Brieﬂy, nematodes were
grown on nematode growth medium (NGM) plates
seeded with Escherichia coli OP50 strain at 20 C. The
transgenic AT3q130 strain used in this work was previ-
ously described by Teixeira-Castro et al. (2011). All
assays were performed at room temperature (20 C) on
4-day-old synchronized animals grown at 20 C.C. elegans drug treatment and motility assay
AT3q130 animals were grown in liquid culture in a 96-well
plate format, with the combination of LiCl and CCI-779.
Four-day-old animals were transferred from the 96-well
plates onto an unseeded NGM plate (equilibrated at
20 C). Plates were allowed to dry for 1 h before starting
the assays. Motility assays were performed at 20 C as
previously described (Gidalevitz et al., 2006; Teixeira-
Castro et al., 2011). Animals remaining inside a 1-cm cir-
cle after one min were scored as locomotion defective.
Motor behavior assays were run in triplicates or quadrupli-
cates (n= 3 or 4), with a total of at least 150 animals
tested per compound concentration. Compound prepara-
tion: Stock solution of 200 mM LiCl (1.05679-0100,
Merck, Darmstadt, Germany) was prepared in water.
CCI-779 (T8040, LC-laboratories, Woburn, MA, United
States) 48.5 mM stock solution was prepared in EtOH.
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All procedures with mice were conducted in accordance
with European regulations (European Union Directive
2010/63/EU). Animal facilities and the people directly
involved in animal experiments (S.D.S., A.N.C.) were
certiﬁed by the Portuguese regulatory entity—Direcc¸a˜o
Geral de Alimentac¸a˜o e Veterina´ria.
All the protocols performed were approved by the
Animal Ethics Committee of the Life and Health
Sciences Research Institute, University of Minho.Mouse strains, maintenance and general methods
In this study we used male CMVMJD135 mice
(background C57BL/6) (Silva-Fernandes et al., 2014a).
Transgenic and wt drug- and placebo-treated animals
were sequentially assigned and housed at weaning in
groups of ﬁve animals in ﬁlter-topped polysulfone cages
267  207  140 mm (370 cm2 ﬂoor area) (Tecniplast,
Buguggiate, Italy), with corncob bedding (Scobis Due,
Mucedola SRL, Settimo Milanese, Italy) in a conventional
animal facility. The progeny produced by mating MJD
transgenic with wild-type animals were genotyped by
PCR, as previously described (Silva-Fernandes et al.,
2010). The experiment started at 4 weeks and ended at
24 weeks of age. The experimenter was not blind to the
study. All animals were maintained under standard labora-
tory conditions: an artiﬁcial 12-h light/dark cycle (lights on
from 8:00 to 20:00 h), with an ambient temperature of 21
± 1 C and a relative humidity of 50–60%; the mice were
given a standard diet (4RF25 during the gestation and
postnatal periods, and 4RF21 after weaning, Mucedola
SRL, Settimo Milanese, Italy) and water ad libitum. Health
monitoring was performed according to FELASA guideli-
nes (Nicklas et al., 2002), conﬁrming the Speciﬁed Patho-
gens status of sentinel animals maintained in the same
animal room. Humane endpoints for the experiment were
deﬁned as previously described (Duarte-Silva et al.,
2014). The timeline used in this study is shown in Fig. 2A.Drug treatment
In order to conduct this pre-clinical trial we used a
combination of two FDA-approved compounds, LiCl
(Merck, Darmstadt, Germany) and CCI-779 (LC
Laboratories, Woburn, MA, United States). Mice were
allocated to vehicle and LiCl + CCI-779-treated groups
(vehicle-treated CMVMJD135, n= 12; LiCl + CCI-779-
treated CMVMJD135, n= 10; vehicle-treated wt, n=
12; LiCl + CCI-779-treated wt, n= 15). The treatment
started at the asymptomatic age of 5 weeks. Animals
were intraperitoneally injected three times a week in the
testing room and immediately placed in their home cage,
except in the week of behavioral tests. Transgenic and wt
animals were treated with 10.4 mg/kg of LiCl and 20 mg/
kg of CCI-779 (doses and routes as previously described
by Wood and Morton (2003), Ravikumar et al. (2004),
Watase et al. (2007), Duarte-Silva et al. (2014)). LiCl stock
solutions were prepared at a concentration of 25 mg/kg in
0.15 M NaCl, 5% Tween-20 and 5% PEG 400 and CCI-
779 at 50 mg/kg in absolute ethanol. Control animals weregiven a placebo injection of buﬀer (0.15 M NaCl, 5%
Tween-20 and 5% PEG 400) with the same frequency.Body weight
All mice were weighed a week before the start of the drug
treatment (4 weeks) and then at 8, 12, 16, 20 and
24 weeks of age.Behavioral tests
The behavioral tests herein shown were performed as
previously described (Duarte-Silva et al., 2014; Silva-
Fernandes et al., 2014b).Western-blot
Mouse brain tissue was prepared as previously described
(Duarte-Silva et al., 2014). The conditions used for
incubation with primary antibodies are as follows: rabbit
anti-p62 (1:50, Abcam, Cambridge, UK) and rabbit anti-
Beclin-1 (1:1000, Cell signaling, Beverly, MA), mouse
anti-beta-actin (Ambion, 1:5000, Life Technologies, CA,
USA), rabbit anti-LC3 (1:1000 Novus Biologicals, Little-
ton, CO) and rabbit anti-ataxin3 serum (1:5000; kindly
provided by Dr. Henry Paulson). The secondary antibod-
ies were incubated at the following dilutions: anti-rabbit
(1:10,000, Biorad, California, USA) and anti-mouse
(1:10,000, Biorad, California, USA). Antibody aﬃnity
was detected by chemiluminescence (Clarity ECL kit, Bio-
rad, California, USA). Western-blot quantiﬁcations were
performed using the Chemidoc XRS Software with Ima-
geLab Software (Biorad, California, USA) according to
the manufacturer’s instructions and using beta-actin as
the loading control.Immunohistochemistry
The animals (24-week-old CMVMJD135 LiCl + CCI-779-
treated and untreated) were deeply anesthetized using a
mixture of medetomidine (0.3 mg/kg) and ketamine
hydrochloride (150 mg/kg) and transcardially perfused
with saline (0.9%) followed by paraformaldehyde 4%.
The brains were extracted and post-ﬁxed with
paraformaldehyde for 72 h and embedded in paraﬃn
using standard procedures. 4-lm-thick brain sections
were subjected to standard immunohistochemistry
procedure. Brieﬂy, the slides were treated with 1 M
citrate buﬀer (antigen retrieval), the endogenous
peroxidases were blocked (3% H2O2) and then
incubated with mouse anti-ATXN3 (1H9, 1:500,
MAB5360, Millipore). After several washing steps, the
slides were incubated with a biotinylated anti-polyvalent
antibody followed by detection using biotin–streptavidin
coupled to horseradish peroxidase and the reaction with
DAB (3,30-diaminobenzidine) substrate (Lab VisionTM
Ultra-VisionTM dectection kit, Thermo Scientiﬁc). ATXN3
nuclear inclusions in the pontine nuclei for CMVMJD135-
treated and -untreated groups (n= 3 for each group,
four slides per animal) were counted and normalized for
total area using the Olympus BX51 stereological
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system software (Visiopharma).Statistical analysis
The experimental unit used in this study was a single
animal. Power analysis was used to determine the
sample size as previously described (Silva-Fernandes
et al., 2014b). The estimates of required number of ani-
mals for speciﬁc behavioral tests and time-points of anal-
ysis are described in (Duarte-Silva et al., 2014).
Continuous variables with normal distributions (K–S test
p> 0.05) were evaluated with the Student t-test or a
two-way ANOVA (Factors: genotype and treatment).
Behavioral data were analyzed using non-parametric
Mann–Whitney U-test when variables were non-
continuous or when a continuous variable did not present
a normal distribution (Kolmogorov–Smirnov test
p< 0.05). Contingency tables (Fisher’s exact test) were
used for categorical variables in the SHIRPA protocol. A
one-Way ANOVA was used for paired comparisons. All
statistical analyses were performed using SPSS 22.0
(SPSS Inc., Chicago, IL, USA). A critical value for signif-
icance of p< 0.05 was used throughout the study.RESULTS
LiCl + CCI-779 treatment improved locomotion
deﬁcits in a transgenic C. elegans model of MJD
We evaluated compound eﬃcacy to rescue neuronal
dysfunction in a C. elegans model of MJD pathogenesis,
in which expression of mutant ATXN3 (AT3q130) in all
neuronal cells results in locomotion defects (Teixeira-
Castro et al., 2011). AT3q130 animals grown in liquid
medium with or without drugs for four days were tested
for defects in locomotion, by employing a motility assay.
Treatment with LiCl and CCI-779 resulted in a partial res-
cue of locomotion impairment (Fig. 1). Taking theseFig. 1. AT3q130 animals treatment with the small molecules target-
ing autophagy. (A) AT3q130 animals treated with 7.5 mM of LiCl
+ CCI-779 at 1 lM showed a signiﬁcant reduction in locomotion
defects given by the motility assay. Data are mean ± SD, at least
150 animals per data point, *p< 0.05 (One way ANOVA).results in consideration, we pursued with this potential
combinatory treatment by performing a pre-clinical trial
in an MJD mouse model.LiCl + CCI-779 treatment eﬀects in the CMVMJD135
mouse model
The CMVMJD135 transgenic mice, expressing full-length
human ataxin-3 with an expanded polyQ repeat of 135
glutamines ubiquitously and at near endogenous levels,
have previously been shown to develop a slowly
progressive motor and neuropathological phenotype
resembling MJD (Silva-Fernandes et al., 2014a). We trea-
ted these mice with LiCl + CCI-779 at dosages previously
described, for each compound individually, to activate
autophagy and not to be toxic (10.4 and 20 mg/kg, respec-
tively) (Wood and Morton, 2003; Ravikumar et al., 2004;
Duarte-Silva et al., 2014). We started the treatment regi-
men at 5 weeks of age (one week before the onset of
the symptoms) and followed the animals until they
reached 24 weeks, performing a monthly extensive char-
acterization of the animals using the SHIRPA protocol
and the Beam walk test. The study design is summarized
in Fig. 2A. Before the beginning of injections, at 4 weeks of
age, mice were evaluated using the SHIRPA protocol, and
no diﬀerences were observed between wild-type and
transgenic animals.Survival and general health
Survival is not a useful readout in pre-clinical trials using the
CMVMJD135model, because animals, although very sick,
survive until quite late ages; however, during this pre-
clinical trial three transgenic animals treated with LiCl
+ CCI-779 died (while none of the untreated animals
died, p= 0.006), which we attribute to the toxicity of the
compounds when administered together. At the end of
the experiment, both CMVMJD135 and wt mice treated
with LiCl + CCI-779 presented an unhealthy
appearance, but were still able to move and feed.
Administration of LiCl + CCI-779 to wt mice caused a
signiﬁcant decrease in the body weight in comparison to
the vehicle group (p= 0.002). This drug combination
treatment also diminished signiﬁcantly the already
reduced body weight of CMVMJD135 mice when
compared to the vehicle-treated transgenic group
(p= 0.001) (Fig. 2B).SHIRPA protocol
At 8, 16, 20 and 24 weeks of age, we observed a
decreased exploratory activity in vehicle-treated
CMVMJD135 mice, while transgenic animals treated
with LiCl + CCI-779 showed an increased exploratory
activity at 8, 16 and 24 weeks of age, given by the
signiﬁcant increase in the number of rears in the viewing
jar (p= 0.001, p= 0.04 and p= 0.003, respectively),
reaching a comparable performance to the wt vehicle-
treated group (Fig. 3A). However, at eight weeks of age,
there was an increase in exploratory behavior in wild-
type mice treated with LiCl + CCI-779, suggesting a
non-speciﬁc eﬀect (Fig. 3A). CMVMJD135 mice treated
Fig. 2. Eﬀect of LiCl + CCI-779 treatment on body weight of CMVMJD135 and wild-type mice. (A) Schematic timeline for the behavioral analysis of
LiCl + CCI-779 pre-clinical trial. (B) The body weight in grams between 8 and 24 weeks of age is depicted for wt and CMVMJD135 mice treated with
LiCl + CCI-779 or vehicle (n= 10–12 for each group). Symbols represent mean ± SEM of the diﬀerent groups. *represents p< 0.05, for genotype
factor (two-way ANOVA). Vertical arrow represents the onset of the phenotype.
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increase in the locomotor activity when compared to
vehicle-treated CMVMJD135 animals at 8 and 12 weeks
of age (p= 0.022 and p= 0.016, respectively)
(Fig. 3B). Of notice, at the age of 12 weeks we could
not observe statistically signiﬁcant diﬀerences between
wt and CMVMJD135 vehicle-treated groups, meaning
that the phenotype was not yet installed for these
parameters (exploratory behavior and locomotor
activity). No positive eﬀect of the LiCl + CCI-779
treatment was observed in the hanging wire test (grip
strength) in CMVMJD135 mice (Fig. 3C). In fact, this
combinatory treatment signiﬁcantly worsened this
symptom at 8 weeks of age when comparing untreated-
CMVMJD135 with treated mice (p= 0.01). Also, the
grip strength (hanging wire test) of LiCl + CCI-779-
treated wt animals was always worse than that of
vehicle-treated wt animals. Regarding tremors, we
observed a slight improvement in CMVMJD135 mice at
24 weeks of age (p= 0.038) (Fig. 4A), as seen
previously with LiCl treatment (Duarte-Silva et al.,
2014). We observed no therapeutic eﬀect of LiCl +
CCI-779 treatment on gait quality and limb clasping
(Fig. 4B, C). The limb clasping reﬂex increased with dis-
ease progression, being statistically diﬀerent only at
24 weeks of age. Importantly, at 16 and 20 weeks of
age, the LiCl + CCI-779 treatment actually worsened
limb clasping in the transgenic animals when compared
to CMVMJD135-vehicle animals (Fig. 4C, labeled with
#) (p= 0.05 and 0.008, respectively).Foot printing test
Footprint patterns of wt and CMVMJD135 transgenic
mice treated with vehicle or LiCl + CCI-779 wereanalyzed for the presence of foot dragging. In
agreement with previous observations (Duarte-Silva
et al., 2014; Silva-Fernandes et al., 2014b), at 12 weeks
of age this phenotype was established in the
CMVMJD135-vehicle animals (p= 2  105), while the
wt-vehicle animals never presented foot dragging. LiCl
+ CCI-779 treatment was not able to improve foot
dragging, and actually showed a trend to worsen the phe-
notype, given by the presence of foot dragging in the
wt-treated animals and a higher percentage of LiCl
+ CCI-779-treated CMVMJD135 mice with this pheno-
type at 12 weeks of age (90% of CMVMJD135-vehicle
animals vs. 100% of CMVMJD135-treated animals
showed foot dragging) (Fig. 4D). At 20 weeks of age all
the transgenic animals analyzed presented this pheno-
type (p= 2  105).Beam walk test
The beam walk test was performed at 20 and 24 weeks of
age, when the phenotype of CMVMJD135 mice in this
motor test is well established (Silva-Fernandes et al.,
2014b). In this particular pre-clinical trial, most of the
transgenic animals treated with LiCl + CCI-779 were
unable to perform the task, as shown in Fig. 5. At
20 weeks of age in the 11-mm circle beam, only three
(in a total of ten animals) were able to cross the beam
(Fig. 5A); these animals performed well in terms of
latency to cross the square beam (12 mm), where seven
animals concluded the task, but at this time-point we did
not observe statistically signiﬁcant diﬀerences among wt
and CMVMJD135-vehicle animals, and no diﬀerences
for treated animals (Fig. 5B). Later on, at 24 weeks of
age, none of the CMVMJD135-treated mice were able
to perform the beam walk test, either in the square or
Fig. 3. LiCl + CCI-779 treatment eﬀect on spontaneous exploratory activity and hindlimb strength. (A) Transgenic animals displayed decreased
vertical locomotor activity at 8 weeks of age and subsequent ages, while CMVMJD135-treated mice showed an increased activity at 8, 16 and
24 weeks of age (n= 10–12 for each group). (B) Transgenic animals traveled less in the arena than wild-type animals at 20 and 24 weeks of age;
LiCl + CCI-779 treatment increased locomotor activity at 8 and 12 weeks of age (n= 10–12 for each group). (C) On the hanging wire test all
transgenic animals displayed a worse performance in holding the grid with age (from 8 to 24 weeks of age). A maximum time of 2 min was given to
each animal and the time that they took to fall was registered (n= 10–12 for each group). Symbols represent mean ± SEM of the diﬀerent groups.
*, **, *** represent p< 0.05, 0.01 or 0.001, respectively, for genotype factor (two-way ANOVA). Red asterisks represent factor treatment in the
analysis (CMVMJD135 mice vs. CMVMJD135-treated mice). Vertical arrow represents the onset of the phenotype. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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sonable to consider that LiCl + CCI-779 treatment had
detrimental eﬀects on the transgenic animals, reﬂected
in this balance-dependent task.
Autophagy induction after LiCl + CCI-779 chronic
treatment
In order to verify autophagy induction after LiCl + CCI-
779 combination treatment, we measured in the
brainstem of transgenic animals the levels of
the autophagy markers LC3 (the classical marker of the
autophagosomes; by analyzing the conversion of LC3I
to LC3II) (Klionsky et al., 2012), Beclin-1 (a protein
involved in the nucleation step of the autophagosome for-
mation) (Itakura et al., 2008) and p62 (a scavenger pro-
tein that signals ubiquitylated proteins toward the
autophagic machinery that directly interacts with LC3,
being itself degraded by autophagy) (Bjorkoy et al.,
2005) (Fig. 6A–C, respectively). Similarly to what we
observed for LiCl treatment alone (Duarte-Silva et al.,
2014), this combined treatment was able to increase the
expression of Beclin-1 (p= 0.007), which is associated
with autophagy initiation, to increase the LC3II/LC3I ratio,
and to decrease the protein levels of the autophagy sub-strate p62 (p= 0.03), conﬁrming increased autophagic
ﬂux. The degree of autophagy induction was, however,
not signiﬁcantly diﬀerent between LiCl and LiCl +
CCI-779 treatments when considering Beclin-1 and p62
autophagy markers (Fig. 6). Due to technical issues, we
were not able to perform the Western-blotting analysis
for LC3 using the combined and single treatment samples
in the same blot membrane. Nevertheless, the assess-
ment using the LC3-II/LC3/I ratio actually suggests the
opposite, as we saw an increase of approximately 7-fold
for the combined treatment, whereas in our previous
study with LiCl only (Duarte-Silva et al., 2014) we had
seen a 1.3-fold increase. So the results with diﬀerent
autophagy markers are not fully concordant regarding
the relative extent of activation of autophagy of the com-
bined versus single treatment.
LiCl + CCI-779 treatment eﬀect on ataxin-3 protein
levels and aggregation
To test the eﬀect of the combinatory drug treatment on
steady-state ataxin-3 levels we performed Western-blot
analysis. Levels of mutant ataxin-3 in the brainstem of
CMVMJD135 showed to be reduced upon LiCl + CCI-
779 chronic treatment (Fig. 7A) (p= 0.04). Furthermore,
Fig. 4. Eﬀect of LiCl + CCI-779 treatment on limb clasping, tremors and gait quality. (A) CMVMJD135 mice presented tremors from 16 weeks of
age onward. In the last time-point analyzed (24 weeks) LiCl + CCI-779 treatment slightly improved this phenotype (n= 10–12 for each group). (B)
CMVMJD135 animals had abnormal gait at 20 and 24 weeks of age (qualitative assessment) which was not reverted by LiCl + CCI-779 (n= 10–12
for each group). (C) Limb clasping was observed in CMVMJD135 mice at 24 weeks of age; LiCl + CCI-779 treatment anticipated the onset of this
symptom, starting in the CMVMJD135-treated group at 16 weeks of age. Red # represents a worse phenotype observed in the treated group. (D)
CMVMJD135 mice drag their feet since 12 weeks of age, which was not improved by LiCl + CCI-779 treatment (n= 10–12 for each group).
Symbols represent mean ± SEM of the diﬀerent groups. *, **, *** represent p< 0.05; 0.01 or 0.001, respectively (Fisher’s exact test).
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quantiﬁed in the pontine nuclei of treated and untreated
CMVMJD135 mice at 24 weeks of age (end of the trial).
LiCl + CCI-779 combined treatment signiﬁcantly
decreased the aggregate load in this brain region
(Fig. 7B, C) (p= 0.0026).DISCUSSION
Based on the concept of autophagy induction as a
potential therapeutic strategy for neurodegenerative
diseases, here we have tested the eﬀect of treatment
with a combination of LiCl and CCI-779 in a mouse
model of MJD. It has been demonstrated in another
mouse model of this disease that CCI-779 treatment, at
the same dosage as used in this work (20 mg/kg),
resulted in an improvement of motor coordination
(Menzies et al., 2010). However, the mouse model used
had a very mild phenotype, observable only in the
Rotarod and non-signiﬁcantly diﬀerent from the controls.
The CMVMJD135 mouse model allowed us to further test
this type of therapeutic strategy, due to its more severephenotype and broad range of disease features. Further-
more, the combination of an autophagy-inducing com-
pound with an mTOR-dependent and another with an
mTOR-independent mode of action was used to test the
therapeutic value of simultaneously modifying these com-
plementary pathways.
Our ﬁrst signiﬁcant observation was that both wt and
transgenic animals treated with LiCl + CCI-779 had a
signiﬁcant decrease in body weight during the treatment
period. The body weight loss in both groups could be
due to an exacerbated activation of autophagy in some
tissues by the combination of these two drugs
(although, unexpectedly, this enhanced induction was
not observed with all autophagy markers in the brain),
and/or it could reﬂect some systemic toxicity of this drug
combination, also patent in the death of 30% of the
treated animals, even though the doses used in this
work for autophagy activation had already been tested
in mice and shown not to be toxic, when administered
separately (Wood and Morton, 2003; Ravikumar et al.,
2004; Duarte-Silva et al., 2014). In fact, the LiCl dosage
used here can be considered low (LiCl plasma levels of
Fig. 5. Eﬀect of LiCl + CCI-779 treatment on balance and motor
coordination. Each bar corresponds to the mean of two consecutive
trials in (A) circle and (B) square beams. The time to traverse the
beam was videotaped and then measured by the same experimenter.
10–12 animals were used for each condition. CMVMJD135-treated
mice showed severe diﬃculties in performing this task. * represents
the p< 0.05 for genotype factor (two-way ANOVA). Black arrows
highlight the low or null number of CMVMJD135-treated mice able to
perform the task.
Fig. 6. Autophagy induction by the chronic treatment with LiCl + CCI-77
transgenic animals injected with vehicle (n= 3) or LiCl + CCI-779 (n= 3); (
animals injected with vehicle (n= 3) or LiCl + CCI-779, at 10.4 and 20 m
lysates of transgenic animals injected with vehicle (n= 3) or LiCl + CCI-779
loading control. *, **, represents p< 0.05 or 0.01, respectively (One-Way AN
S. Duarte-Silva et al. / Neuroscience 313 (2016) 162–173 1690.3 ± 0.09 mmol/L, as estimated previously by us
(Duarte-Silva et al., 2014)), being below the therapeutic
range used in humans with bipolar disorder (Lin et al.,
2006; Duarte-Silva et al., 2014). The toxicity here
observed may be related to cellular pathways activated
or altered speciﬁcally by these two compounds when
administered together.
Concerning the neurological phenotype, the eﬀects of
the combination therapy were generally not positive. The
ﬁrst manifestation of the disease in the CMVMJD135
model is loss of limb strength, which severely
progresses with age (Silva-Fernandes et al., 2014b).
Chronic LiCl + CCI-779 treatment did not improve this
muscular strength deﬁcit, in accordance to other treat-
ments previously performed in same model (Duarte-
Silva et al., 2014; Silva-Fernandes et al., 2014a). Since
this phenotype starts early in life and progresses dramat-
ically fast, the treatment regimen that we performed (start-
ing one week before the appearance of the loss of
muscular strength) may have been insuﬃcient in terms
of duration to rescue this deﬁcit. Furthermore, the com-
bined treatment herein tested appeared to have detrimen-
tal eﬀects in treated-CMVMJD135 mice; additionally, this
negative impact was also observed in wt animals, which
performed worse in this task than vehicle-treated wt mice
(although the diﬀerence did not reach statistical
signiﬁcance).
Results concerning other neurological parameters
also point to very limited therapeutic eﬀects and even
some neurotoxicity of the drug combination, namely
concerning limb clasping and gait quality, for which the
treated transgenic mice presented a more severe
phenotype than the vehicle-treated CMVMJD135
animals. Furthermore, the combination of LiCl + CCI-
779 had a negative impact on the foot printing pattern of
wt animals, since it was possible to detect dragging of9. (A) Western-blot analysis of LC3 levels in brainstem lysates of
B) Western-blot analysis of beclin-1 in brainstem lysates of transgenic
g/kg, respectively (n = 3); (C) Western-blot analysis of p62 in brain
at 10.4 and 20 mg/kg, respectively (n= 3); beta-actin was used as
OVA).
Fig. 7. LiCl + CCI-779 treatment eﬀect on ataxin-3 levels. (A) Western-blot analysis of ATXN3 in brainstem lysates of transgenic animals injected
with vehicle (n= 4) or LiCl + CCI-779, at 10.4 and 20 mg/kg, respectively (n= 4); beta-actin was used as loading control. (B) Representative
images of anti-ataxin-3 immunohistochemistry in the pontine nuclei of 24-week-old CMVMJD135 untreated (a and b, n= 3, 4 slides per animals)
and treated (c and d, n= 3, 4 slides per animal). Scale bar for a and c 50 lm and for b and d 20 lm. (C) quantiﬁcation of the number of aggregates
in the pontine nuclei. *, ** represents the p< 0.05 or 0.01, respectively (One-Way ANOVA).
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treated wt animals. LiCl + CCI-779-treated CMVMJD135
animals also showed severe diﬃculties in the beam walk
test; at 24 weeks of age these animals were not able to
perform the task in the easier beam (square), while
vehicle-treated CMVMJD135 animals at the same age
were able to cross this beam (albeit taking longer than
wt animals, due to motor deﬁcits associated with the
disease). In addition, when diﬃculty was enhanced by
using the round narrower beam, this worsening of the
phenotype became detectable at 20 weeks of age. In
fact, the neurotoxic eﬀect of the LiCl + CCI-779
combination treatment is strongly visible in this
behavioral test, not allowing the comparative analysis
between CMVMJD135 mice (treated vs. vehicle).
Intriguingly, chronic treatment with LiCl + CCI-779
increased the vertical exploratory behavior in both wt
and CMVMJD135 mice. Similar eﬀects, also occurring in
wt and CMVMJD135-treated animals, were detected in
the spontaneous activity, given by the number of
squares traveled in the arena. We had previously shown
that LiCl treatment resulted in increased exploratory
behavior in these mice (Duarte-Silva et al., 2014), sug-
gesting that the increase observed in the current study
may be due to non-speciﬁc eﬀects of this drug, most likely
not disease-related.
We also observed a slight improvement of the
tremors, which is in agreement with our previous result
using LiCl alone in these mice (Duarte-Silva et al.,
2014), suggesting that this improvement might be due
to that component of the treatment regimen. The pres-
ence of tremors in human patients is a rare event and
can be treated with levodopa (Coutinho and Sequeiros,
1981; Ishida et al., 1998; Nandagopal and Moorthy,2004; Bettencourt et al., 2011), so this improvement
may not be very relevant in the disease context.
In summary, these results demonstrate the negative
impact of the combination of these two autophagy-
inducing compounds when administered simultaneously,
even in dosages that, upon single compound
administration, were safe for mice (Wood and Morton,
2003; Ravikumar et al., 2004; Duarte-Silva et al., 2014).
Thus, if any future LiCl + CCI-779 combination therapy
is to be considered for MJD or other polyQ, it would be
necessary to adjust the doses of both compounds to
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